Cover Image
市場調查報告書

Opioids(類鴉片物質)引起的副作用 - 開發中產品分析

Opioid Induced Side Effects - Pipeline Review, H1 2014

出版商 Global Markets Direct 商品編碼 307306
出版日期 內容資訊 英文 41 Pages
訂單完成後即時交付
價格
Back to Top
Opioids(類鴉片物質)引起的副作用 - 開發中產品分析 Opioid Induced Side Effects - Pipeline Review, H1 2014
出版日期: 2014年06月30日 內容資訊: 英文 41 Pages
簡介

Opioids(類鴉片物質)引起的副作用主要是睡意、暈眩、反胃、嘔吐、便秘、生理性依賴、抗藥性、呼吸抑制等,其他還有胃內物排放緩慢、痛覺過敏、免疫功能及荷爾蒙功能不全,肌肉僵硬,肌抽躍等。可使用Opioids(類鴉片物質)補助藥的NSAID和補助止痛藥來減輕副作用。

本報告提供Opioids(類鴉片物質)引起的副作用之治療藥開發情形調查分析,提供您開發中產品概要、臨床實驗的各階段產品概要、主要企業簡介、藥物簡介、開發中產品的最新趨勢、最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

Opioids(類鴉片物質)引起的副作用概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:大學/研究機關別

開發中產品的概要

  • 後期階段的產品
  • 初期階段的產品

開發中的產品:各企業

調查中的產品:大學/研究機關別

治療藥的開發企業

  • 鹽野義製藥
  • Cortex Pharmaceuticals, Inc.
  • Charleston Laboratories, Inc.

治療藥的評估

  • 單獨療法的產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • naldemedine
  • CL-108
  • CX-2007
  • CX-2076
  • CLH-5
  • CLH-10
  • OFQ Peptide

開發中產品的最新趨勢

暫停中的計劃

產品開發的里程碑

  • 關註資訊和新聞稿

附錄

圖表

目錄
Product Code: GMDHC5180IDB

Summary

Global Markets Direct's, 'Opioid Induced Side Effects - Pipeline Review, H1 2014', provides an overview of the Opioid Induced Side Effects's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Opioid Induced Side Effects, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Opioid Induced Side Effects and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Opioid Induced Side Effects
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Opioid Induced Side Effects and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Opioid Induced Side Effects products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Opioid Induced Side Effects pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Opioid Induced Side Effects
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Opioid Induced Side Effects pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Opioid Induced Side Effects Overview
  • Therapeutics Development
    • Pipeline Products for Opioid Induced Side Effects - Overview
    • Pipeline Products for Opioid Induced Side Effects - Comparative Analysis
  • Opioid Induced Side Effects - Therapeutics under Development by Companies
  • Opioid Induced Side Effects - Therapeutics under Investigation by Universities/Institutes
  • Opioid Induced Side Effects - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Opioid Induced Side Effects - Products under Development by Companies
  • Opioid Induced Side Effects - Products under Investigation by Universities/Institutes
  • Opioid Induced Side Effects - Companies Involved in Therapeutics Development
    • Shionogi & Co., Ltd.
    • Cortex Pharmaceuticals, Inc.
    • Charleston Laboratories, Inc.
  • Opioid Induced Side Effects - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • naldemedine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CL-108 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CX-2007 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CX-2076 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CLH-5 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CLH-10 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OFQ Peptide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Opioid Induced Side Effects - Recent Pipeline Updates
  • Opioid Induced Side Effects - Dormant Projects
  • Opioid Induced Side Effects - Product Development Milestones
    • Featured News & Press Releases
      • May 19, 2014: Elite Pharmaceuticals Initiates Pivotal Bioequivalence Study for Third Opioid Abuse Deterrent Product
      • Dec 09, 2013: Acura Pharmaceuticals Provides Update on Its Abuse Deterrent Hydrocodone/Acetaminophen Combination Drug Development
      • Jul 18, 2013: Collegium Pharmaceutical Announces Notice of Allowance for U.S. Patent Covering Oxycodone DETERx, an Abuse-Deterrent, Extended-Release Opioid Product
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Opioid Induced Side Effects, H1 2014
  • Number of Products under Development for Opioid Induced Side Effects - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Number of Products under Investigation by Universities/Institutes, H1 2014
  • Comparative Analysis by Late Stage Development, H1 2014
  • Comparative Analysis by Early Stage Development, H1 2014
  • Products under Development by Companies, H1 2014
  • Products under Investigation by Universities/Institutes, H1 2014
  • Opioid Induced Side Effects - Pipeline by Shionogi & Co., Ltd., H1 2014
  • Opioid Induced Side Effects - Pipeline by Cortex Pharmaceuticals, Inc., H1 2014
  • Opioid Induced Side Effects - Pipeline by Charleston Laboratories, Inc., H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Stage and Target, H1 2014
  • Number of Products by Stage and Mechanism of Action, H1 2014
  • Number of Products by Stage and Route of Administration, H1 2014
  • Number of Products by Stage and Molecule Type, H1 2014
  • Opioid Induced Side Effects Therapeutics - Recent Pipeline Updates, H1 2014
  • Opioid Induced Side Effects - Dormant Projects, H1 2014

List of Figures

  • Number of Products under Development for Opioid Induced Side Effects, H1 2014
  • Number of Products under Development for Opioid Induced Side Effects - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Comparative Analysis by Early Stage Products, H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Top 10 Target, H1 2014
  • Number of Products by Stage and Top 10 Target, H1 2014
  • Number of Products by Top 10 Mechanism of Action, H1 2014
  • Number of Products by Stage and Top 10 Mechanism of Action, H1 2014
  • Number of Products by Top 10 Molecule Type, H1 2014
  • Number of Products by Stage and Top 10 Molecule Type, H1 2014
Back to Top